Search Page
Save citations to file
Email citations
Email address has not been verified. Go to
My NCBI account settings
to confirm your email and then refresh this page.
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2023 | 1 |
| 2025 | 2 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26.
Lancet. 2023.
PMID: 37385275
Clinical Trial.
Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.
Heerspink HJL, Friedman AN, Bjornstad P, van Raalte DH, Cherney D, Cao D, Garcia-Pérez LE, Stefanski A, Turfanda I, Bunck MC, Benabbad I, Griffin R, Piras de Oliveira C.
Heerspink HJL, et al.
J Am Soc Nephrol. 2025 Jun 13. doi: 10.1681/ASN.0000000764. Online ahead of print.
J Am Soc Nephrol. 2025.
PMID: 40512543
No abstract available.
Item in Clipboard
Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial.
Hunter Gibble T, Cao D, Zhang XM, Xavier NA, Poon JL, Fitch A.
Hunter Gibble T, et al.
Diabetes Ther. 2025 May;16(5):977-991. doi: 10.1007/s13300-025-01723-w. Epub 2025 Mar 22.
Diabetes Ther. 2025.
PMID: 40120035
Free PMC article.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.